Ximelagatran, an emerging new direct, oral, fixed-dose thrombin inhibitor may offer an attractive alternate to warfarin for patients with nonvalvular atrial fibrillation. The lack of drug-to-drug interactions and need for coagulation monitoring parameters such as international normalized ratio and a short half-life make therapeutic control and withdrawal in the event of bleeding easier. The side-effect profile, including elevation of liver enzymes, may temper the clinical utility of long-term use ximelagatran.
Fuster V , Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force of Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol38:1231-1265, 2001
2.
Go AS , Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA285:2370-2375, 2001
3.
Wattigney WA , Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: Implications for primary prevention. Circulation108:711-716, 2003
4.
Wolf PA , Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med158:229-234, 1998
5.
Wolf PA , Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. Arch Intern Med147:1561-1564, 1987
6.
Dulli DA , Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology22:118-123, 2003
7.
Wang TJ , Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA290:1049-1056, 2003
8.
Atrial Fibrillation Investigators , Atrial Fibrillation, Aspirin, Anticoagulation Study, European Atrial Fibrillation Study, Stroke Prevention in Atrial Fibrillation Study, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Study, Veterans Affairs Prevention in Atrial Fibrillation Study: Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med158:1316-1320, 1998
9.
Manning WJ , Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi: A prospective, intraoperative study. Ann Intern Med123:817-822, 1995
10.
SPAF Investigators Committee on Echocardiography : Transesophageal echocardiographic correlates of thrombo embolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med128:639-647, 1998
11.
Gustafsson C , Blomback M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke21:47-51, 1990
12.
Feng D , D’Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (the Framingham Offspring Study). Am J Cardiol87:168-171, 2001
13.
Leong F , Blann AD, Lip GYH. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am J Cardiol86:795-797, 2000
14.
Heppell RM , Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart77:407-411, 1997
15.
Mitusch R , Siemens HJ, Garbe M, et al. Detection of a hypercoagulable state in novalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost75:219-223, 1996
16.
Nagao T , Hamamoto M, Kanda A, et al. Platelet activation is not involved in acceleration of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke26:1365-1368, 1995
17.
Cai H , Li Z, Goette A, Mera F, et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: Potential mechanisms for atrial thrombosis and stroke. Circulation106:2854-2858, 2002
18.
Hart RG : Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med138:831-838, 2003
19.
Goldman ME , Pearce LA, Hart RGet al, for the Stroke Prevention in Atrial Fibrillation Investigators: Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr12:1080-1087, 1999
20.
Sohara H , Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol29:106-112, 1997
21.
Cai H , Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res87:840-844, 2000
22.
Hylek EM , Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med349:1019-1026, 2003
23.
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med347:1825-1833, 2002
24.
Hart RG , Benavente O, McBride R, Pearce LA. Anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med131:492-501, 1999
25.
van Walraven C , Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA288:2441-2448, 2002
26.
Mann KG . Thrombin formation. Chest124(suppl):4S-10S, 2003
27.
Nesheim M . Thrombin and fibrinolysis. Chest124(suppl):33S-39S, 2003
28.
Brass LF . Thrombin and platelet activation. Chest124(suppl):18S-25S, 2003
29.
Hirsh J , Dalen JE, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest119:8S-21S, 2001
Go AS , Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med131:927-934, 1999
32.
Bungard TJ , Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin?Arch Intern Med160:41-46, 2000
33.
Di CeraE. Thrombin interactions . Chest124(3 Suppl):15S-17S, 2003
34.
Esmon CT . The protein C pathway. Chest124(3 Suppl):26S-32S, 2001
35.
Mann KG , Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol23:17-25, 2003
36.
Lefokovits J , Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation90:1522-1536, 1994
37.
Weitz JI . A novel approach to thrombin inhibition. Thromb Res109:S17-S22, 2003
38.
Eikelboom J , White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol41(suppl 4):705-785, 2003
39.
Gustafson D , Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review. Thromb Res109(suppl):S9-S15, 2003
40.
Halperin JL , and the Executive Steering Committee, on behalf of the SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of studies and baseline characteristics (SPORTIF III and V). Am Heart J146:431-438, 2003
41.
Executive Steering Committee on behalf of the SPORTIF Investigators . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet362:1691-1698, 2003
42.
Halperin JL . Stroke prevention using the direct oral thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: SPORTIF V. Presented at: AHA Scientific Sessions 2003; Nov 11, 2003; Orlando, FL
43.
Jeffery S . FDA panel recommends against approval of all indications for ximelagatran. Heartwire News, Sept 14, 2004
44.
Wood S . FDA opts not to approve ximelagatran. Heartwire News, Oct 4, 2004
